Marker Therapeutics, Inc. (NASDAQ:MRKR) Sees Significant Decrease in Short Interest

Marker Therapeutics, Inc. (NASDAQ:MRKRGet Free Report) saw a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 107,900 shares, a drop of 27.9% from the March 15th total of 149,700 shares. Based on an average daily volume of 21,000 shares, the days-to-cover ratio is currently 5.1 days. Currently, 1.7% of the shares of the company are short sold.

Institutional Investors Weigh In On Marker Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Marker Therapeutics by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 225,057 shares of the company’s stock worth $1,238,000 after purchasing an additional 3,975 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Marker Therapeutics during the 4th quarter worth $45,000. Renaissance Technologies LLC boosted its stake in shares of Marker Therapeutics by 7.7% during the 4th quarter. Renaissance Technologies LLC now owns 163,200 shares of the company’s stock worth $43,000 after acquiring an additional 11,700 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Marker Therapeutics by 255.8% during the 4th quarter. Northern Trust Corp now owns 38,711 shares of the company’s stock worth $213,000 after acquiring an additional 27,830 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its stake in shares of Marker Therapeutics by 1,000.0% during the 4th quarter. International Assets Investment Management LLC now owns 11,000 shares of the company’s stock worth $60,000 after acquiring an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Trading Down 6.3 %

MRKR stock traded down $0.29 on Friday, hitting $4.31. The company had a trading volume of 20,306 shares, compared to its average volume of 20,837. Marker Therapeutics has a 12-month low of $0.76 and a 12-month high of $9.68. The stock’s 50-day simple moving average is $4.27 and its 200 day simple moving average is $3.95.

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells.

Recommended Stories

Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.